Many bispecific antibodies bind to CD3 of the TCR and to an antigen on the cancer cells, e.g., EpCAM on carcinomas such as breast and prostate cancer (Catumaxomab and Solitomab), Her/neu on breast cancer cells (Ertumaxomab), PSMA on prostate cancer cells (Pasotuxizumab), or BCMA (B cell maturation antigen) on myeloma cells (AMG420) [333]. Here, FOLH1 is linked to prostate carcinoma.